0      0

JL1121ES - JL1121ES: Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial

‐ Oct 24, 2023 11:00am

Full author listing 

Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Jeanny B. Aragon-Ching, MD, FACP, Inova Schar Cancer Institute, Fairfax, VA, USA. Miguel A. Climent Duran, MD, Instituto Valenciano de Oncología, Valencia, Spain. Srikala S. Sridhar, MD, MSc, FRCPC, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Thomas Powles, MD, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, UK. Paul Cislo, PhD, Pfizer, New York, NY, USA. Elisabete Michelon, MD, PhD, Pfizer, New York, NY, USA. Alessandra di Pietro, MD, PhD, Pfizer srl, Milano, Italy. Petros Grivas, MD, PhD, University of Washington; Fred Hutchinson Cancer Center, Seattle, WA USA


You must be logged in and own this session in order to post comments.